NEWS

Phenox Inc. announces the presentation of the PROST Clinical Trial at th...

[Irvine, CA] - phenox Inc. a leading medical device company in the Neurovascular industry, announced the presentation of the primary results of The pRESET for Occlusive Stroke Treatment (PROST) Randomized Clinical Trial at the International Stroke Conference in Dallas, TX on February 8th at 9:30am CST. This highly anticipated event marks a significant milestone in the company's efforts to advance the treatment of occlusive stroke.

Phenox Inc. a Wallaby Medical Company, announces the FDA 510k Clearance...

Phenox Inc., a leading medical device company in the Neurovascular industry, announced today that its pRESET Thrombectomy Device has received FDA clearance for use to treat acute ischemic stroke. The pRESET product family, which has been available in Europe for over 10 years, is now cleared for use in the United States.

“Tough clots" special feature, second edition

Recurrence after coiling of a pericallosal aneurysm

Now on air: podcast episode #6 featuring Dr. Adam Arthur

Day 2 at LINNC Asia 2022!

Day 1 at LINNC Asia 2022!

Vesalio appoints VP of U.S. Sales and announces recent publication on Ne...

Nashville, Tennessee - (NOV 29, 2022) – VESALIO is pleased to welcome Bob Bushok as Vice President of U.S. Sales overseeing commercial strategy and execution for the NeVa VSTM vasospasm launch and the expected 2023 introduction of NeVa™ thrombectomy platform into the U.S. market. Bob will be responsible for building the U.S. sales team and will play a pivotal role in continuing to grow the company through strategic initiatives.

T-stent-assisted coiling of a complex Acom aneurysm

World Stroke Day 2022 Special Report